Select Publications
Journal articles
2023, 'Epidemiology of injecting drug use, prevalence of injecting-related harm, and exposure to behavioural and environmental risks among people who inject drugs: a systematic review', The Lancet Global Health, 11, pp. e659 - e672, http://dx.doi.org/10.1016/S2214-109X(23)00057-8
,2023, 'Global coverage of interventions to prevent and manage drug-related harms among people who inject drugs: a systematic review', The Lancet Global Health, 11, pp. e673 - e683, http://dx.doi.org/10.1016/S2214-109X(23)00058-X
,2023, '“You'll come in and dose even in a global pandemic”: A qualitative study of adaptive opioid agonist treatment provision during the COVID-19 pandemic', International Journal of Drug Policy, 114, http://dx.doi.org/10.1016/j.drugpo.2023.103998
,2023, 'Single-visit hepatitis C point-of-care testing, linkage to nursing care, and peer-supported treatment among people with recent injecting drug use at a peer-led needle and syringe program: The TEMPO Pilot Study', International Journal of Drug Policy, 114, http://dx.doi.org/10.1016/j.drugpo.2023.103982
,2023, 'A national programme to scale-up decentralised hepatitis C point-of-care testing and treatment in Australia', The Lancet Gastroenterology and Hepatology, 8, pp. 204 - 207, http://dx.doi.org/10.1016/S2468-1253(22)00355-7
,2023, 'Associations between the prevalence of chronic hepatitis B among people who inject drugs and country-level characteristics: An ecological analysis', Drug and Alcohol Review, 42, pp. 569 - 581, http://dx.doi.org/10.1111/dar.13595
,2023, 'Hepatitis C care cascade before and during the direct-acting antiviral eras in New South Wales, Australia: A population-based linkage study', Journal of Viral Hepatitis, 30, pp. 250 - 261, http://dx.doi.org/10.1111/jvh.13791
,2023, 'Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study', Liver International, 43, pp. 569 - 579, http://dx.doi.org/10.1111/liv.15469
,2023, 'Evaluation of Simplified HCV Diagnostics in HIV/HCV Co-Infected Patients in Myanmar', Viruses, 15, pp. 521, http://dx.doi.org/10.3390/v15020521
,2023, 'Health-related quality of life in people receiving opioid agonist treatment and treatment for hepatitis C virus infection', Journal of Addictive Diseases, 41, pp. 213 - 224, http://dx.doi.org/10.1080/10550887.2022.2088978
,2023, 'Hepatitis C virus-specific immune responses following direct-acting antivirals administered during recent hepatitis C virus infection', Journal of Viral Hepatitis, 30, pp. 64 - 72, http://dx.doi.org/10.1111/jvh.13761
,2023, 'Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis', International Journal of Drug Policy, 111, http://dx.doi.org/10.1016/j.drugpo.2022.103917
,2023, 'People engaged in opioid agonist treatment as a counterpublic during the COVID-19 pandemic in Australia: A qualitative study', Drug and Alcohol Review, 42, pp. 203 - 212, http://dx.doi.org/10.1111/dar.13531
,2023, 'Recomendaciones para el manejo de la infección por el virus de la hepatitis C entre usuarios de drogas por vía parenteral', International Journal of Drug Policy, 111, http://dx.doi.org/10.1016/j.drugpo.2015.11.011
,2023, 'Recommandations pour la prise en charge de l'infection par le virus de l'hépatite C chez les usagers de drogues par injection', International Journal of Drug Policy, 111, pp. 101669, http://dx.doi.org/10.1016/j.drugpo.2015.11.009
,2023, 'Decentralised point-of-care testing for acute, chronic and infectious disease – benefits and challenges', Pathology, 55, pp. S7 - S7, http://dx.doi.org/10.1016/j.pathol.2022.12.029
,2022, 'Awareness of hepatitis C virus infection status among people who inject drugs in a setting of universal direct-acting antiviral therapy: The ETHOS Engage study', International Journal of Drug Policy, 110, http://dx.doi.org/10.1016/j.drugpo.2022.103876
,2022, 'Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study', Clinical Infectious Diseases, 75, pp. 1809 - 1819, http://dx.doi.org/10.1093/cid/ciac246
,2022, 'Awareness of HCV Status and Preferences for Testing and Treatment among People with Recent Injecting Drug Use at a Peer-Led Needle and Syringe Program: The TEMPO Pilot Study', Viruses, 14, http://dx.doi.org/10.3390/v14112463
,2022, 'Diagnostic Accuracy of Assays Using Point-of-Care Testing or Dried Blood Spot Samples for the Determination of Hepatitis C Virus RNA: A Systematic Review', Journal of Infectious Diseases, 226, pp. 1005 - 1021, http://dx.doi.org/10.1093/infdis/jiac049
,2022, 'Reinfection and Risk Behaviors After Treatment of Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy A Cohort Study', Annals of Internal Medicine, 175, pp. 1221 - 1229, http://dx.doi.org/10.7326/M21-4119
,2022, '“You need a designated officer” – Recommendations from correctional and justice health personnel for scaling up hepatitis C treatment-as-prevention in the prison setting', International Journal of Drug Policy, 106, http://dx.doi.org/10.1016/j.drugpo.2022.103746
,2022, 'Prevalence and factors associated with hospitalisation for bacterial skin infections among people who inject drugs: The ETHOS Engage Study', Drug and Alcohol Dependence, 237, http://dx.doi.org/10.1016/j.drugalcdep.2022.109543
,2022, 'A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study', Viruses, 14, http://dx.doi.org/10.3390/v14071555
,2022, 'Timely Hepatitis C RNA Testing and Treatment in the Era of Direct-Acting Antiviral Therapy among People with Hepatitis C in New South Wales, Australia', Viruses, 14, pp. 1496, http://dx.doi.org/10.3390/v14071496
,2022, 'Willingness of people who inject drugs to participate in a randomised controlled trial involving financial incentives to initiate hepatitis C treatment', Drug and Alcohol Dependence, 235, http://dx.doi.org/10.1016/j.drugalcdep.2022.109438
,2022, 'A Global Systematic Review of Hepatitis C Elimination Efforts through Micro-Elimination', Seminars in Liver Disease, 42, pp. 159 - 172, http://dx.doi.org/10.1055/a-1777-6112
,2022, 'Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals', JHEP Reports, 4, pp. 100462, http://dx.doi.org/10.1016/j.jhepr.2022.100462
,2022, 'Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study', The Lancet Gastroenterology and Hepatology, 7, pp. 396 - 415, http://dx.doi.org/10.1016/S2468-1253(21)00472-6
,2022, 'Interventions to enhance testing, linkage to care, and treatment initiation for hepatitis C virus infection: a systematic review and meta-analysis', The Lancet Gastroenterology and Hepatology, 7, pp. 426 - 445, http://dx.doi.org/10.1016/S2468-1253(21)00471-4
,2022, '‘Not just one box that you tick off’ – Deconstructing the hepatitis C care cascade in the interferon-free direct acting antiviral era from the client perspective', International Journal of Drug Policy, 102, http://dx.doi.org/10.1016/j.drugpo.2022.103610
,2022, 'Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence', International Journal of Drug Policy, 100, http://dx.doi.org/10.1016/j.drugpo.2021.103492
,2022, '“That was quick, simple, and easy”: Patient perceptions of acceptability of point-of-care hepatitis C RNA testing at a reception prison', International Journal of Drug Policy, 99, http://dx.doi.org/10.1016/j.drugpo.2021.103456
,2022, 'Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study.', Int J Drug Policy, 105, pp. 103706, http://dx.doi.org/10.1016/j.drugpo.2022.103706
,2021, 'Considering treatment-as-prevention scale-up for Australian prisons: a qualitative sub-study of expert stakeholders from the Australian ‘surveillance and treatment of prisoners with hepatitis C’ project (SToP-C)', Harm Reduction Journal, 18, pp. 46, http://dx.doi.org/10.1186/s12954-021-00494-4
,2021, 'Hepatitis C treatment as prevention in the prison setting: Assessments of acceptability of treatment scale up efforts by prison correctional and health personnel', International Journal of Drug Policy, 98, http://dx.doi.org/10.1016/j.drugpo.2021.103379
,2021, 'Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study', Clinical Infectious Diseases, 73, pp. 2037 - 2044, http://dx.doi.org/10.1093/cid/ciab526
,2021, 'Concordance between self-reported and current hepatitis C virus infection status in a sample of people who inject drugs in Sydney and Canberra, Australia', Drug and Alcohol Review, 40, pp. 1349 - 1353, http://dx.doi.org/10.1111/dar.13282
,2021, 'Evaluating the Prevention Benefit of HCV Treatment: Modeling the SToP-C Treatment as Prevention Study in Prisons', Hepatology, 74, pp. 2366 - 2379, http://dx.doi.org/10.1002/hep.32002
,2021, 'Hepatitis C virus cascade of care among people who inject drugs in Australia: Factors associated with testing and treatment in a universal healthcare system', Drug and Alcohol Dependence, 228, http://dx.doi.org/10.1016/j.drugalcdep.2021.109050
,2021, 'Prescribing of direct-acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program', Medical Journal of Australia, 215, pp. 332 - 333, http://dx.doi.org/10.5694/mja2.51204
,2021, 'Diversity of incarceration patterns among people who inject drugs and the association with incident hepatitis C virus infection', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103419
,2021, 'Expert stakeholder perspectives on the acceptability of treatment-as-prevention in prison: a qualitative substudy of the ‘Surveillance and Treatment of Prisoners with Hepatitis C’ project (SToP-C)', Addiction, 116, pp. 2761 - 2769, http://dx.doi.org/10.1111/add.15477
,2021, 'Global cascade of care for chronic hepatitis C virus infection: A systematic review and meta-analysis', Journal of Viral Hepatitis, 28, pp. 1340 - 1354, http://dx.doi.org/10.1111/jvh.13574
,2021, 'Injecting frequency trajectories and hepatitis C virus acquisition: Findings from a cohort of people who inject drugs in Montréal, Canada', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103439
,2021, 'Non-fatal opioid overdose, naloxone access, and naloxone training among people who recently used opioids or received opioid agonist treatment in Australia: The ETHOS Engage study', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103421
,2021, 'Progress and remaining challenges to address hepatitis C, other infectious diseases, and drug-related harms to improve the health of people who use drugs', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103469
,2021, 'Reinfection following successful direct-acting antiviral therapy for HCV infection among people attending an inner-city community health centre in Victoria, Canada', International Journal of Drug Policy, 96, http://dx.doi.org/10.1016/j.drugpo.2021.103418
,2021, 'Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection', Journal of Hepatology, 75, pp. 829 - 839, http://dx.doi.org/10.1016/j.jhep.2021.04.056
,2021, 'Association of Opioid Agonist Treatment with All-Cause Mortality and Specific Causes of Death among People with Opioid Dependence: A Systematic Review and Meta-analysis', JAMA Psychiatry, 78, pp. 979 - 993, http://dx.doi.org/10.1001/jamapsychiatry.2021.0976
,